JERSEY CITY MEDICAL CENTER
1. Target Overview & Investment Thesis
JERSEY CITY MEDICAL CENTER is a 289-bed suburban community hospital in HUDSON, NJ with $456.8M in net patient revenue and a -13.7% operating margin. The hospital serves a payer mix of 17.5% Medicare, 7.9% Medicaid, and 74.6% commercial.
Thesis: Undervalued. Our ML models identify $33.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -13.7% to -6.4% (+736bps).
| Net Revenue HCRIS | $456.8M |
| Current EBITDA COMPUTED | $-62.7M |
| Operating Margin COMPUTED | -13.7% |
| Occupancy HCRIS | 62.4% |
| Revenue / Bed COMPUTED | $1.6M |
| Net-to-Gross HCRIS | 21.0% |
| Distress Probability ML | 44.9% |
2. Market Context & Competitive Position
NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of -13.7% places it below the state median. Among 49 size-comparable peers (144-578 beds), the median margin is -4.3%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (144-578), prioritizing same-state peers. 49 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| JERSEY CITY MEDICAL CENTER (Target) | NJ | 289 | $456.8M | -13.7% |
| COOPERMAN BARNABAS MEDICAL CEN | NJ | 554 | $1.07B | -4.3% |
| ENGLEWOOD HOSPITAL & MED CTR | NJ | 292 | $967.3M | 0.1% |
| THE VALLEY HOSPITAL | NJ | 385 | $951.8M | 17.5% |
| OVERLOOK MEDICAL CENTER | NJ | 440 | $880.2M | 8.9% |
| ATLANTICARE REGIONAL MEDICAL C | NJ | 532 | $791.4M | 2.3% |
| CAPITAL HEALTH MED CENTER - HO | NJ | 209 | $746.8M | 0.8% |
| KENNEDY UNIVERSITY HOSPITAL | NJ | 546 | $724.5M | -8.5% |
| UH - UNIVERSITY HOSPITAL | NJ | 358 | $702.0M | -27.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $33.6M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $9.6M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $9.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $9.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $5.6M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $292K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-62.7M |
| + RCM Uplift | +$33.6M |
| Pro Forma EBITDA | $-29.1M |
| Current Margin | -13.7% |
| Pro Forma Margin | -6.4% |
| WC Released (1x) | $17.5M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-96.5M | $-77.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-96.5M | $-116.6M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-86.8M | $-37.0M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-86.8M | $-66.0M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-106.1M | $-214.3M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-106.1M | $-270.2M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 49 hospitals with 144-578 beds
- Same-state prioritization (n=50)
- Comp margins: P25=-14.8% / P50=-4.3% / P75=2.3%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.